In one of the largest acquisitions of a drug this year, Takeda has agreed to buy a drug in mid-stage development for autoimmune diseases for $4 billion upfront plus $2 billion in milestone payments from Cambridge-based Nimbus Therapeutics.
In one of the largest acquisitions of a drug this year, Takeda has agreed to buy a drug in mid-stage development for autoimmune diseases for $4 billion upfront plus $2 billion in milestone payments from Cambridge-based Nimbus Therapeutics.
